A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
← catalyst calendarNCT06966453 · readout in 432 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
100estimated
Sites
166
Countries
Australia, Brazil, Canada +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-30 | actual | When the study began enrolling |
| Primary completion | 2027-10-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-01-27 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Breast Cancer
- Breast Neoplasms
Intervention
- Drug: Disitamab vedotin — also filed as RC48, RC48-ADC
Primary outcome
what the primary-completion date above is the date OFObjective response (OR) by investigator assessment
measured From Cycle 1 Day 1 until disease progression by investigator assessment per RECIST version 1.1, or death due to any cause, whichever is earlier; up to approximately 2 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed